Key Points
- Burning Rock Biotech director Yusheng Han made a large insider purchase, buying 111,110 shares at $9.00 each for a total of $999,990. The transaction increased his direct stake to 18,018,546 shares, worth about $162.2 million.
- Han has been actively buying shares in multiple recent transactions, including several purchases in mid-to-late June totaling millions of dollars. These repeated buys suggest notable insider confidence in the company.
- The stock has been volatile but was up 9.6% in Friday trading, opening at $9.82, while the company reported a narrower-than-expected quarterly loss earlier in June. Despite the earnings beat on EPS, analysts still rate BNR a consensus “Sell.”
Burning Rock Biotech Limited Sponsored ADR (NASDAQ:BNR - Get Free Report) Director Yusheng Han acquired 5,990 shares of the company's stock in a transaction that occurred on Tuesday, June 23rd. The shares were bought at an average cost of $7.50 per share, for a total transaction of $44,925.00. Following the acquisition, the director directly owned 18,129,186 shares in the company, valued at $135,968,895. This represents a 0.03% increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Yusheng Han also recently made the following trade(s):
- On Friday, June 26th, Yusheng Han bought 24,900 shares of Burning Rock Biotech stock. The stock was bought at an average price of $8.00 per share, with a total value of $199,200.00.
- On Wednesday, June 24th, Yusheng Han bought 250,000 shares of Burning Rock Biotech stock. The shares were bought at an average cost of $8.00 per share, with a total value of $2,000,000.00.
- On Monday, June 22nd, Yusheng Han purchased 104,650 shares of Burning Rock Biotech stock. The shares were bought at an average price of $7.45 per share, for a total transaction of $779,642.50.
- On Tuesday, June 16th, Yusheng Han purchased 111,110 shares of Burning Rock Biotech stock. The stock was purchased at an average cost of $9.00 per share, for a total transaction of $999,990.00.
- On Friday, June 12th, Yusheng Han acquired 210,000 shares of Burning Rock Biotech stock. The stock was purchased at an average price of $9.25 per share, with a total value of $1,942,500.00.
- On Thursday, June 11th, Yusheng Han acquired 24,760 shares of Burning Rock Biotech stock. The shares were purchased at an average cost of $8.74 per share, with a total value of $216,402.40.
Burning Rock Biotech Stock Performance
Burning Rock Biotech stock opened at $9.82 on Friday. Burning Rock Biotech Limited Sponsored ADR has a 1-year low of $3.23 and a 1-year high of $41.72. The company has a current ratio of 3.05, a quick ratio of 2.81 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $103.31 million, a PE ratio of -11.98 and a beta of 1.32. The firm's 50 day simple moving average is $12.57 and its 200 day simple moving average is $20.04.
Burning Rock Biotech (NASDAQ:BNR - Get Free Report) last announced its quarterly earnings results on Tuesday, June 9th. The company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($2.29) by $2.09. The firm had revenue of $15.66 million during the quarter, compared to the consensus estimate of $19.21 million. Burning Rock Biotech had a negative net margin of 11.57% and a negative return on equity of 10.98%.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently added to or reduced their stakes in BNR. Marshall Wace LLP bought a new position in Burning Rock Biotech in the fourth quarter valued at $220,000. Prospera Financial Services Inc lifted its stake in Burning Rock Biotech by 26.0% during the fourth quarter. Prospera Financial Services Inc now owns 31,185 shares of the company's stock worth $628,000 after purchasing an additional 6,430 shares during the last quarter. Renaissance Technologies LLC lifted its stake in Burning Rock Biotech by 13.8% during the first quarter. Renaissance Technologies LLC now owns 35,407 shares of the company's stock worth $571,000 after purchasing an additional 4,290 shares during the last quarter. Finally, Crcm LP boosted its holdings in shares of Burning Rock Biotech by 13.8% in the 3rd quarter. Crcm LP now owns 221,575 shares of the company's stock worth $1,917,000 after purchasing an additional 26,809 shares in the last quarter. 30.03% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
Several equities analysts recently commented on BNR shares. Wall Street Zen cut Burning Rock Biotech from a "buy" rating to a "hold" rating in a research report on Saturday, June 13th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Burning Rock Biotech in a report on Monday, April 20th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has an average rating of "Sell".
Read Our Latest Stock Analysis on BNR
Burning Rock Biotech Company Profile
(
Get Free Report)
Burning Rock Biotech (NASDAQ: BNR) is a precision oncology company specializing in the development and commercialization of next-generation sequencing (NGS)–based cancer diagnostics. The company's core business revolves around liquid biopsy tests, which analyze circulating tumor DNA (ctDNA) from blood samples to detect genetic mutations associated with various solid tumors. By enabling noninvasive profiling of tumor genomics, Burning Rock Biotech aims to guide personalized therapy decisions and monitor treatment response in cancer patients.
Founded in 2014 and headquartered in Guangzhou, China, Burning Rock Biotech launched its first clinical services in the mid-2010s and subsequently expanded its laboratory network across major Chinese cities.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
